{
  "id": "5a74a4be0384be9551000004",
  "type": "yesno",
  "question": "Are there RNAi approaches considered for the treatment of kidney injury?",
  "ideal_answer": "Yes, RNAi approaches are being considered for the treatment of kidney injury.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27009268"
  ],
  "snippets": [
    {
      "text": "Herein, we describe ammonium-functionalized carbon nanotube (fCNT)-mediated transport of siRNA selectively and with high efficiency to renal proximal tubule cells in animal models of acute kidney injury (AKI).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27009268",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "fCNT enhanced siRNA delivery to tubule cells compared to siRNA alone and effectively knocked down the expression of several target genes, includingTrp53,Mep1b,Ctr1, andEGFP A clinically relevant cisplatin-induced murine model of AKI was used to evaluate the therapeutic potential of fCNT-targeted siRNA to effectively halt the pathogenesis of renal injury. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27009268",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The nanocarbon-mediated delivery of siRNA provides a therapeutic means for the prevention of AKI to safely overcome the persistent barrier of nephrotoxicity during medical intervention.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27009268",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}